Pharmaceutical company
Appears in 15 stories · Last updated Nov 10, 2026
Prior collaborator
Every medicine argenx sells today reaches patients by infusion or injection. On Nov. 9, 2026, the Dutch immunology company agreed to pay $550 million in cash for a Santa Cruz company whose chemistry is built to make pills instead.
Updated 1 hour ago
Testing an injectable Factor XIa antibody
Roughly a quarter of the 795,000 Americans who have a stroke each year have had one before. On Monday the Food and Drug Administration approved Sunharbo, a daily pill from Bayer that cuts the risk of a second ischemic stroke by 26% when taken alongside existing antiplatelet therapy.
Updated Yesterday
Sponsor of Lp(a)HORIZON; halting pelacarsen development for cardiovascular disease
For five years, 8,322 people who had already survived a heart attack or stroke injected either pelacarsen or a placebo every month. The drug did what it was designed to do: it cut lipoprotein(a), a cholesterol-carrying particle, by 78%. Major cardiovascular events occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group.
Updated 3 days ago
Maker of Zolgensma; reporting the tumor cases to regulators
Nine children who received Zolgensma, a one-time gene therapy for spinal muscular atrophy, later developed tumors. In two of the three cases tested, Novartis found evidence the virus used to deliver the treatment had inserted itself into the patient's DNA.
Updated 4 days ago
Original developer of VQW-765 and licensor to Vanda
Vanda Pharmaceuticals' experimental anxiety drug failed its 546-patient Phase III trial, and the company has put the program on hold. VQW-765 matched placebo on a public-speaking stress test in adults with social anxiety disorder.
Updated Oct 19
As of October 2026: Licensee; secures exclusive worldwide rights to ABO2203 and option rights on other Abogen RNA programs
Novartis agreed to pay up to $7.8 billion for rights to Chinese biotech Abogen's mRNA therapeutics. The deal includes a $575 million upfront payment and an exclusive worldwide license to ABO2203, the first mRNA-encoded T-cell engager to reach clinical testing in autoimmune disease.
Updated Oct 2
As of September 2026: Paused three autoimmune CAR-T trials after participant deaths
Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.
Updated Sep 24
As of September 2026: Competitor; markets Fabhalta (iptacopan) for IgAN
Roche's experimental IgA nephropathy drug sefaxersen met its phase 3 primary endpoint on September 23, cutting proteinuria versus placebo at 37 weeks in the IMAgINATION study. The result, from a prespecified interim look, was strong enough that Roche is taking it to health authorities and planning a medical meeting presentation.
Updated Sep 23
As of September 2026: Rival with ianalumab under FDA review
Sjögren's disease has no approved treatment in the US. Amgen just moved a step closer to ending that.
Updated Sep 22
As of September 2026: Competitor and ITM's largest lutetium-177 customer
Telix Pharmaceuticals, an Australian maker of cancer imaging and treatment agents, agreed on September 21 to buy German isotope producer ITM Isotope Technologies Munich. The deal is worth up to $2.35 billion all-in, with $1.65 billion paid upfront, most of it in Telix shares.
Updated Sep 21
As of September 2026: Investing $1.1B into new Campus Point headquarters
A venue called The Alexandria at 4150 Campus Point Court in San Diego applied for a California liquor license. The application appeared on the state's ABC licensing list on September 18, 2026.
Updated Sep 18
As of September 2026: Facing investor pressure after two phase 3 failures
Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.
Updated Sep 8
As of July 2026: Manufacturer of Kymriah, first FDA-approved CAR-T therapy
Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns and nearly ended the field.
Updated Jul 3
As of May 2026: Incumbent competitor in CML market with Scemblix
Keytruda, the world's best-selling drug, generated $31.7 billion for Merck in 2025 — roughly 40% of the company's total revenue. Its key U.S. patents expire in 2028, and when they do, cheaper copies will enter the market and that revenue will begin to evaporate. Merck has now spent over $25 billion on three acquisitions in nine months to build the portfolio that will need to replace it.
Updated May 30
As of May 2026: Competitor; developing oral BTK inhibitor for food allergy
For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.
Updated May 22
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
